据血色素报告,在患强性白血病的第三病人中,CAR-T治疗取得了成功,显示没有可检测的癌症细胞,符合安全标准。 Hemogenyx reports successful CAR-T treatment in third patient with aggressive leukemia, showing no detectable cancer cells and meeting safety standards.

据血激素制药公司报告,第三名病人在HG-CT-1第一阶段试验中成功治疗了HG-CT-1,这是一种CAR-T疗法,用于治疗复发性或骨折性急性流血白血病。 Hemogenyx Pharmaceuticals reports the successful treatment of the third patient in its Phase I trial of HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia. 治疗耐受性良好,符合安全标准,并显示出早期疗效迹象,患者没有可检测到AML细胞. The treatment was well-tolerated, met safety criteria, and showed early signs of efficacy, with no detectable AML cells in the patient. 前三个病人的安全数据将由一个独立的委员会审查,以确定是否可进行剂量升级。 Safety data from the first three patients will be reviewed by an independent board to determine if dose escalation can proceed. 审判的目的是评估安全性、功效、存活率和反应时间。 The trial aims to assess safety, efficacy, survival rates, and response duration.